Published in JAMA Ophthalmol on April 01, 2014
Associations between abnormal rod-mediated dark adaptation and health and functioning in older adults with normal macular health. Invest Ophthalmol Vis Sci (2014) 1.65
VEGF regulates local inhibitory complement proteins in the eye and kidney. J Clin Invest (2016) 1.39
Age-related macular degeneration: insights into inflammatory genes. J Ophthalmol (2014) 0.98
Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci (2016) 0.97
Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine (2016) 0.95
Apolipoprotein E promotes subretinal mononuclear phagocyte survival and chronic inflammation in age-related macular degeneration. EMBO Mol Med (2015) 0.89
Serum cytokines as biomarkers for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2014) 0.87
Gut microbiota influences pathological angiogenesis in obesity-driven choroidal neovascularization. EMBO Mol Med (2016) 0.83
Prevalence of anti-retinal autoantibodies in different stages of Age-related macular degeneration. BMC Ophthalmol (2014) 0.82
Association of Psychosocial Conditions, Oral Health, and Dietary Variety with Intellectual Activity in Older Community-Dwelling Japanese Adults. PLoS One (2015) 0.80
The Association Between Subretinal Drusenoid Deposits in Older Adults in Normal Macular Health and Incident Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci (2016) 0.79
Interleukin-1β Level Is Increased in Vitreous of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV). PLoS One (2015) 0.79
Mitochondrial DNA has a pro-inflammatory role in AMD. Biochim Biophys Acta (2015) 0.78
Targeting MAPK Signaling in Age-Related Macular Degeneration. Ophthalmol Eye Dis (2016) 0.77
Repurposing an orally available drug for the treatment of geographic atrophy. Mol Vis (2016) 0.77
Inflammatory Mechanisms of Age-related Macular Degeneration. Int Ophthalmol Clin (2015) 0.76
The broad-spectrum chemokine inhibitor NR58-3.14.3 modulates macrophage-mediated inflammation in the diseased retina. J Neuroinflammation (2016) 0.76
High-Salt Enhances the Inflammatory Response by Retina Pigment Epithelium Cells following Lipopolysaccharide Stimulation. Mediators Inflamm (2015) 0.76
Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration? Autoimmun Rev (2017) 0.76
Responses of Multipotent Retinal Stem Cells to IL-1β, IL-18, or IL-17. J Ophthalmol (2015) 0.75
Automation of diagnostics by new disruptive technologies supports local general practice and medical screening in the third world. Australas Med J (2015) 0.75
Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease. Ocul Immunol Inflamm (2014) 0.75
Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci (2016) 0.75
Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. JCI Insight (2016) 0.75
Genetic Association Analysis of Drusen Progression. Invest Ophthalmol Vis Sci (2016) 0.75
Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in ARPE-19 cells. Int J Ophthalmol (2017) 0.75
Genetic pleiotropy between age-related macular degeneration and 16 complex diseases and traits. Genome Med (2017) 0.75
Nutrient patterns and risk of cataract: a case-control study. Int J Ophthalmol (2017) 0.75
The effect of orbital implantation on peripheral blood melatonin and sex hormone levels in child patients with congenital eyeball dysplasia. Exp Ther Med (2017) 0.75
Altered activation state of circulating neutrophils in patients with neovascular age-related macular degeneration. Immun Ageing (2017) 0.75
The relationship between vascular endothelial dysfunction and treatment frequency in neovascular age-related macular degeneration. Jpn J Ophthalmol (2017) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol (2001) 21.37
Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol (2004) 18.86
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol (2004) 13.78
Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology (1992) 10.88
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res (2001) 8.38
The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol (2000) 8.10
The Wisconsin age-related maculopathy grading system. Ophthalmology (1991) 7.62
The Beaver Dam Eye Study: visual acuity. Ophthalmology (1991) 6.87
The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology (1997) 6.47
Oxidative stress: oxidants and antioxidants. Exp Physiol (1997) 6.12
Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol (1976) 5.73
A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol (2002) 5.57
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology (2007) 3.96
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med (1995) 3.91
Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology (2002) 3.80
Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol (2003) 3.40
Changes in visual acuity in a population. The Beaver Dam Eye Study. Ophthalmology (1996) 2.98
Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol (2006) 2.77
Changes in visual acuity in a population over a 10-year period : The Beaver Dam Eye Study. Ophthalmology (2001) 2.71
Oxidative damage and protection of the RPE. Prog Retin Eye Res (2000) 2.65
Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis (2002) 2.53
The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol (2006) 2.37
Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol (2005) 2.08
Leukocytes and the risk of ischemic diseases. JAMA (1987) 2.03
An update on the genetics of age-related macular degeneration. Mol Vis (2007) 1.95
Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 1.85
Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol (1985) 1.66
Blindness and visual impairment: a public health issue for the future as well as today. Arch Ophthalmol (2004) 1.63
Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A (2006) 1.63
Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med (2012) 1.59
Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med (1999) 1.45
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol (2011) 1.33
Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology (2001) 1.31
Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol (2007) 1.26
Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology (2007) 1.26
Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci (2010) 1.26
Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens (2012) 1.25
Inflammation, complement factor h, and age-related macular degeneration: the Multi-ethnic Study of Atherosclerosis. Ophthalmology (2008) 1.22
Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Arch Ophthalmol (2010) 1.16
Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc Natl Acad Sci U S A (2012) 1.16
C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol (2007) 1.15
Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am J Ophthalmol (2005) 1.15
Incidence of visual impairment over a 20-year period: the Beaver Dam Eye Study. Ophthalmology (2013) 1.14
Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol Biomarkers Prev (2004) 1.14
Application of gas chromatography-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease. Clin Chem Lab Med (2003) 1.11
Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture. Invest Ophthalmol Vis Sci (2010) 1.11
High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol (2007) 1.10
Pigment epithelium-derived factor inhibits oxidative stress-induced cell death by activation of extracellular signal-regulated kinases in cultured retinal pigment epithelial cells. Life Sci (2006) 1.10
Senile macular degeneration. The involvement of giant cells in atrophy of the retinal pigment epithelium. Invest Ophthalmol Vis Sci (1986) 1.05
Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity. Biochem Soc Symp (2003) 1.05
The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol (2005) 1.03
Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension. Antioxid Redox Signal (2005) 1.03
Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration: the Beaver Dam Eye Study. JAMA Ophthalmol (2013) 1.01
Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. Immunobiology (2011) 1.01
Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium. Ophthalmic Epidemiol (2014) 1.01
Complement system activation and endothelial dysfunction in patients with age-related macular degeneration (AMD): possible relationship between AMD and atherosclerosis. Acta Ophthalmol (2011) 0.98
Oxidative stress: the achilles' heel of neurodegenerative diseases of the retina. Front Biosci (Landmark Ed) (2012) 0.97
Plasma biomarkers of oxidative stress and genetic variants in age-related macular degeneration. Am J Ophthalmol (2011) 0.97
Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch Ophthalmol (2005) 0.96
Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study. Atherosclerosis (2013) 0.92
C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts. JAMA Ophthalmol (2013) 0.91
Long-term variability of inflammatory markers and associated factors in a population-based cohort. J Am Geriatr Soc (2013) 0.90
Two genetic pathways for age-related macular degeneration. Curr Opin Genet Dev (2007) 0.88
Evaluation of oxidant stress in dialysis patients. Blood Purif (2000) 0.83
C-reactive protein and age-related macular degeneration and cataract: the singapore malay eye study. Invest Ophthalmol Vis Sci (2009) 0.79
Serum Lipids and Proliferative Diabetic Retinopathy and Macular Edema in Persons With Long-term Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. JAMA Ophthalmol (2015) 0.99
Cross-sectional associations of medication and supplement use with retinal vascular diameter in the Beaver Dam Eye Study. JAMA Ophthalmol (2014) 0.82
Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study. JAMA Ophthalmol (2015) 0.79
Oxidized Low-Density Lipoprotein and the Incidence of Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema Determined From Fundus Photographs. JAMA Ophthalmol (2015) 0.78
Associations Between Methylenetetrahydrofolate Reductase Polymorphisms, Serum Homocysteine Levels, and Incident Cortical Cataract. JAMA Ophthalmol (2016) 0.76
Body Fat Distribution and Diabetic Retinopathy in People With Type 2 Diabetes. JAMA (2016) 0.75